Under the three-year partnership, Targeted Molecular will develop BioFilmChip microarray content, based on its knowledge of signaling pathways, while AutoGenomics will develop the tests on its Infiniti platform.
The first test will be a gene expression assay for tumor response and resistance to compounds targeting the HER1 and HER2 pathways. Future assays will cover breast cancer response to therapies, apoptotic response, and resistance to chemotherapy.